Alpha-1-acid glycoprotein directly affects the pharmacokinetics and the analgesic effect of methadone in the rat beyond protein binding

Journal of Pharmaceutical Sciences

Volumn 93, Issue 11, 2004, Pages 2836-2850

  Rodriguez, Monica ^a   Ortega, Ignacio ^a   Soengas, Itziar ^a   Leal, Nerea ^a   Suarez, Elena ^a   Calvo, Rosario ^a   Lukas, John C ^a,b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Alpha 1 acid glycoprotein; Analgesic effect; Methadone; NONMEM; Pharmacokinetics pharmacodynamics; Population pharmacokinetics; Protein binding

Indexed keywords

METHADONE; OROSOMUCOID; TURPENTINE OIL;

ANALGESIC ACTIVITY; ARTERIAL BLOOD; ARTICLE; BINDING KINETICS; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DISPOSITION; DRUG PROTEIN BINDING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MALE; NONHUMAN; PHARMACODYNAMICS; RAT; REACTION TIME; TAIL FLICK TEST;

EID: 8644226764     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20171     Document Type: Article

References (44)

1. Aguirre C, Troconiz IF, Valdivieso A, Jimenez RM, Gonzalez JP, Calvo R, Rodriguez-Sasiain JM. 1996. Pharmacokinetics and pharmacodynamics of penbutolol in healthy and cancer subjects: Role of altered protein binding. Res Commun Mol Pathol Pharmacol 92:53-72.
2. 3 antagonist, in patients with cancer. Cancer Chemother Pharmacol 42:418-422.
3. Abramson FP. 1982. Methadone plasma protein binding: Alterations in cancer and displacement from alpha-1-acid glycoprotein. Clin Pharmacol Ther 32:652-658.
4. 1-acid glycoprotein (AAG) and serum protein binding of methadone in heroin addicts with abstinence syndrome. Int J Clin Pharmacol Ther 38:35-40.
5. Eap CB, Buclin T, Baumann P. 2002. Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence. Clin Pharmacokinet 41:1153-1193.
6. Garrido MJ, Valle M, Calvo R, Troconiz IF. 1999. Altered plasma and brain disposition and pharmacodynamics of methadone in abstinent rats. J Pharmacol Exp Ther 288:179-187.
7. Chiang J, Hermodsson G, Oie S. 1991. The effect of alpha 1-acid glycoprotein on the pharmacological activity of alpha 1-adrenergic antagonists in rabbit aortic strips. J Pharm Pharmacol 43:540-547.
8. Ette EI, Kelman AW, Howie CA, Whiting B. 1995. Analysis of animal pharmacokinetic data: Performance of the one point per animal design. J Pharmacokinet Biopharm 23:551-566.
9. Jamieson JC, Ashton FE, Friesen AB, Chou B. 1972. Studies on acute phase proteins of rat serum II. Determination of the contents of alpha-1-acid glycoprotein, alpha-2-macroglobulin, and albumin in serum from rats suffering from induced inflammation. Can J Biochem 50:871-880.
10. Keyler DE, Pentel PR, Haughey DB. 1987. Pharmacokinetics and toxicity of high-dose human alpha 1-acid glycoprotein infusion in the rat. J Pharm Sci 76:101-104.
11. Le Bars D, Gozariu M, Cadden SW. 2001. Animal model of nociception. Pharmacol Rev 53:597-652.
12. Wolff K, Hay AW, Raistrick D. 1992. Plasma methadone measurements and their role in methadone detoxification programs. Clin Chem 38:420-425.
13. March C, Blanke RV. 1987. Determination of free valproic acid concentration using the Amicon Micropartition MPS-1 Ultrafiltration system. Ther Drug Monitor 7:115-120.
14. Garrido MJ, Jimenez R, Gomez E, Calvo R. 1996. Influence of plasma-protein binding on analgesic effect of methadone in rats with spontaneous withdrawal. J Pharm Pharmacol 48:281-284.
15. Imamura H, Maruyama T, Okabe H, Shimada H, Otagiri M. 1994. A simple and rapid fluorometric determination method of alpha-1-acid glycoprotein in serum using quinaldine red. Pharm Res 11:566-570.
16. Doumas BT, Watson WA, Biggs HG. 1997. Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chem Acta 258:21-30.
17. Abramson FP, Lutz MP. 1986. The kinetics of induction by rifampin of alpha 1-acid glycoprotein and antypirine clearance in the dog. Drug Metab Dispos 14:46-51.
18. Parivar K, Tolentino L, Taylor G, Oie S. 1992. Elimination of non-reactive and weakly reactive human alpha 1 acid glycoprotein after induction of the acute phase response in rats. J Pharm Pharmacol 44:447-450.
19. Marathe PH, Shen DD, Artru AA, Bowdle TA. 1991. Effect of serum protein binding on the entry of lidocaine into the brain and cerebrospinal fluid in dogs. Anesthesiology 75:804-812.
20. Garcia E, Calvo R, Rodriguez-Sasiain JM, Jimenez R, Troconiz IF, Suarez E. 1995. Resistance of atracurium in rats with experimental inflammation: role of protein binding. Acta Anesthesiol Scand 39:1019-1023.
21. Matsushima H, Watanabe T, Higuchi S. 2000. Effect of alpha(1)-acid glycoprotein on the pharmacokinetics of tamsulosin in rats treated with turpentine oil. J Pharm Sci 89:490-498.
22. Gomez E, Martinez-Jorda R, Suarez E, Garrido MJ, Calvo R. 1995. Altered methadone analgesia due to change in plasma protein binding: Role of the route of administration. Gen Pharmacol 26:1273-1276.
23. Jauregizar N, Calvo R, Suarez E, Quinatana A, Raczka E, Lukas JC. 2001. Altered disposition and effect of lerisetron in rats with elevated alpha-1-acid glycoprotein levels. Pharm Res 18:838-845.
24. Belpaire FM, Bogaert MG, Mugabo P, Rosseel MT. 1986. Binding to serum alpha 1-acid glycoprotein and effect of beta-adrenoreceptor antagonists in rats with inflammation. Br J Pharmacol 88:697-705.
25. Renton KW. 2001. Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther 92:147-163.
26. Sukhai M, Piquette-Miller M. 2000. Regulation of the multidrug resistance genes by stress signals. J Pharm Sci 3:268-280.
27. Zhang XQ, Schooley RT, Gerber JG. 1999. The effect of increasing α-1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors. J Infect Dis 180: 1833-1837.
28. Bilello JA, Bilello PA, Prichard M, Robins T, Drusano GL. 1995. Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease by human serum α-1-acid glycoprotein. J Infect Dis 171:546-551.
29. Jones K, Hoggard PG, Khoo S, Maher B, Back DJ. 2001. Effect of alpha-1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro. Br J Clin Pharmacol 51:99-102.
30. Sadler BM, Gillotin C, Lou Y, Stein DS. 2001. In vivo effect of alpha-1-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 45:852-856.
31. Holladay JW, Dewey MJ, Yoo SD. 1998. Pharmacokinetics and antidepressant activity of fluoxetine in transgenic mice with elevated serum alpha-1-acid glycoprotein levels. Drug Metab Dispos 26: 20-24.
32. Lariviere WR, Chesler EJ, Mogil JS. 2001. Transgenic studies of pain and analgesia: Mutation or background genotype. J Pharmacol Exp Ther 297: 467-473.
33. Fuse E, Tanii H, Takai K, Asanome K, Kurata N, Kobayashi H, Kuwabara T, Kobayashi S, Sugiyama Y. 1999. Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to α-1-acid glycoprotein in humans. Cancer Res 59:1054-1060.
34. Ling GS, Umans JG, Inturrisi CE. 1981. Methadone: Radioimmunoassay and pharmacokinetics in the rat. J Pharmacol Exp Ther 217:147-151.
35. Carlos M, Du Souich P, Lukas JC, Carlos R, Suarez E, Calvo R. 2002. Effect of omeprazole on oral and i.v. RS-methadone: Pharmacokinetics and pharmacodynamics in the rat. J Pharm Sci 91:1627-1638.
36. Olsen GD, Wendel HA, Livermore JD, Leger RM, Lynn RK, Gerber N. 1976. Clinical effects and pharmacokinetics of racemic methadone and its optical isomers. Clin Pharmacol Ther 21:147-157.
37. Holladay JW, Dewey MJ, Michniak BB, Wiltshire H, Halberg DL, Weigl P, Liang Z, Halifax K, Lindup WE, Back DJ. 2001. Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir. Drug Metab Dispos 29:299-303.
38. Sörensson J, Matejka GL, Ohlson M, Haraldsson B. 1999. Human endothelial cells produce orosomucoid, an important component of the capillary barrier. Am J Physiol 276:530-534.
39. Chiang J, Oie S. 1990. Pharmacologic activity of prazosin is decreased by alpha-1-acid glycoprotein "in vivo." J Pharmacol Exp Ther 254:324-329.
40. Huang JD, Oie S. 1985. Influence of serum protein binding on hepatic clearance of S-disopyramide in the rabbit. J Pharm Pharmacol 37:471-475.
41. Guirguis MS, Jamali F. 2003. Disease-induced interaction: Reduced response to propranolol despite increased concentration in the rat with inflammation. J Pharm Sci 92:1077-1084.
42. Kulmatycki KM, Abouchehade K, Sattari S, Jamali F. 2001. Drug-disease interactions: Reduced β-adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat. Br J Pharmacol 133:286-294.
43. Santamarta MT, Pineda J. 2002. Involvement of nitric oxide in the desensitization of μ opioid receptors in rat locus coeruleus. Methods Findings 24(Suppl A):92.
44. Highfield DA, Grant S. 1998. Ng-nitro-L-arginine, an NOS inhibitor, reduces tolerance to morphine in the rat locus coeruleus. Synapse 29:233-239.